UNSPSC 51123106: Encainide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) SY3J0147NB, chemically known as benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+-)- but more generally known as encainide, which bears US NIH Compound Identifier 48033. European Medicines Agency schedules Encainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06519MIG.

UNSPSC 51123106 Encainide, a Commodity code, covers individual pharmaceutical active ingredients and finished medications procured by state and local government health and emergency services. State and local buyers under this code are purchasing specific branded and generic medications for emergency medical services, public health programs, and state pharmacy benefit administration. The City of Tampa's Fire Rescue division, for example, recently solicited advanced life support medications including epinephrine, adenosine, diltiazem, and labetalol through a sealed-bid IFB; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) manages ongoing contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. Issuing bodies include municipal fire and emergency services departments, state health and human services agencies, and cooperative purchasing organizations serving multiple jurisdictions. The code captures both ad hoc, single-source acquisitions for specific emergency medications and broader supply agreements managed through state or regional cooperative vehicles.

Recent activity appears concentrated in the South and Upper Midwest, with Tampa, Texas, and Minnesota-Oregon representing the most recent posted opportunities. The City of Tampa's Bid No. 26-P-00188 for Advanced Life Support Medications closed April 8, 2026, with an estimated contract value of $40,000 and a one-year term renewable for two additional years; the solicitation included a 5 percent SLBE bid discount and required nine-month minimum expiration dates on all supplies. The Texas HHS Commission's RFI (HHS0017013) posted April 3, 2026, seeks vendor capabilities for direct-to-manufacturer prescription programs serving state employee health plans, signaling potential future procurement activity but no current award. MMCAP's RFP (S1070000015802) for generic pharmaceuticals closed March 26, 2026, and represents a two-year cooperative contract with July 1, 2026 effectiveness, requiring vendors to work through three authorized wholesalers and meet cGMP and DSCSA compliance. State and local buyers under this code typically demand firm pricing with included freight, expiration-date warranties, and OSHA Safety Data Sheet compliance, reflecting the life-safety and regulatory constraints of pharmaceutical procurement.